Palvella Therapeutics (NASDAQ:PVLA) Earns “Buy” Rating from HC Wainwright

Palvella Therapeutics (NASDAQ:PVLA)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $38.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 186.79% from the stock’s current price. HC Wainwright also issued estimates for Palvella Therapeutics’ FY2029 earnings at ($0.69) EPS.

Separately, Cantor Fitzgerald began coverage on shares of Palvella Therapeutics in a research note on Wednesday, December 18th. They set an “overweight” rating for the company.

Palvella Therapeutics Price Performance

Shares of Palvella Therapeutics stock opened at $13.25 on Friday. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $22.32. The stock has a market capitalization of $17.49 million, a P/E ratio of -1.10 and a beta of 0.61.

Insider Buying and Selling

In other Palvella Therapeutics news, Director George M. Jenkins bought 4,000 shares of the stock in a transaction on Wednesday, December 18th. The shares were purchased at an average cost of $12.93 per share, with a total value of $51,720.00. Following the completion of the transaction, the director now directly owns 180,671 shares of the company’s stock, valued at $2,336,076.03. This represents a 2.26 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.39% of the stock is currently owned by corporate insiders.